You just read:

Health Canada Approves Astellas' XOSPATA® (gilteritinib) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation

News provided by

Astellas Pharma Canada, Inc.

Jan 14, 2020, 07:07 ET